Group 1 - The company expects a positive net profit for the first half of 2025, indicating an upward trend in performance [1][2] - The performance forecast period is from January 1, 2025, to June 30, 2025 [1] - The company has not yet audited the performance forecast by a registered accounting firm [1] Group 2 - The sales of the veterinary chemical drug segment have been strong, with increased sales of the main product, oxytetracycline, in both domestic and overseas markets [2] - The completion of the company's sixth-phase project has led to increased production capacity, meeting market demand and generating more profit [2] - The agricultural product processing segment has benefited from a decline in corn prices, contributing positively to overall performance [2]
金河生物科技股份有限公司2025年半年度业绩预告